Home › Soft Tissue Sarcoma › NCT02701153

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Histologically confirmed soft tissue sarcoma of the extremity/trunk
* Intermediate or high grade sarcoma
* Resectable primary lesion (patients with pre-existing metastasis will be included if their primary is still going to be resected)
* Recurrent, any grade, no previous radiation therapy
* Karnofsky performance status (KPS) \>= 70 or Eastern Cooperative Oncology Group (ECOG) 0 - 2
* If a woman is of childbearing potential, a negative serum pregnancy test must be documented

Exclusion Criteria:

* Active treatment of a separate malignancy
* History of prior irradiation to the area to be treated
* Pre-operative chemotherapy (post-op acceptable)

About the study

This phase II trial studies the side effects of hypofractionated radiation therapy in treating patients with soft tissue sarcomas prior to surgery. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

What is being tested

• Conventional Surgery (procedure)
• Hypofractionated Radiation Therapy (radiation)
• Laboratory Biomarker Analysis (other)
• Questionnaire Administration (other)

Sponsor: Jonsson Comprehensive Cancer Center · Participants: 51 · Started: Feb 3, 2016

Contact the study team

• Jackie Hernandez · Phone: 310-206-8477

Official record on ClinicalTrials.gov — NCT02701153

Locations in the U.S.

Conditions

• Soft Tissue Sarcoma

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.